Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $3
Hold Rating on Prelude Therapeutics Pending Phase 1 Results of PRT3789
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $4
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $3
Barclays Reaffirms Their Sell Rating on Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Pipeline and Financial Position
Barclays Cuts Prelude to Underweight, Cites Lack of Near-term Catalysts
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects
Prelude Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
H.C. Wainwright Cuts Prelude Therapeutics to Neutral, Cites Valuation
HC Wainwright & Co. Downgrades Prelude Therapeutics to Neutral, Announces $5 Price Target
Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Stock Downgraded to Neutral Amid Anticipation for Trial Results
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Morgan Stanley Downgrades Prelude Therapeutics to Underweight, Lowers Price Target to $4
Prelude Therapeutics Analyst Ratings
No Data